Amyris Inc (AMRS) Insider Sells $50,431.68 in Stock

Amyris Inc (NASDAQ:AMRS) insider John Melo sold 10,776 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the sale, the insider now directly owns 83,172 shares of the company’s stock, valued at $389,244.96. The transaction was disclosed in a filing with the SEC, which is available at this link.

Amyris Inc (NASDAQ:AMRS) traded up $0.03 during mid-day trading on Thursday, reaching $4.91. The company’s stock had a trading volume of 401,162 shares, compared to its average volume of 279,596. Amyris Inc has a 1-year low of $1.86 and a 1-year high of $10.70. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. The company has a market cap of $211.30, a P/E ratio of -0.79 and a beta of 0.16.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04). The business had revenue of $24.20 million during the quarter, compared to analyst estimates of $36.30 million. During the same period last year, the firm earned ($0.07) EPS. Amyris’s revenue for the quarter was down 8.8% compared to the same quarter last year. equities analysts predict that Amyris Inc will post -3.32 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AMRS. Bank of New York Mellon Corp boosted its stake in Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 4,603 shares during the period. Carl Domino Inc bought a new position in Amyris in the 3rd quarter worth approximately $182,000. KBC Group NV boosted its stake in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares during the period. Tanaka Capital Management Inc. boosted its stake in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after purchasing an additional 221,295 shares during the period. Finally, Creative Planning bought a new position in Amyris in the 4th quarter worth approximately $188,000. Institutional investors and hedge funds own 22.84% of the company’s stock.

Several research firms recently issued reports on AMRS. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Amyris in a report on Thursday. Cowen reissued a “hold” rating and issued a $4.00 target price on shares of Amyris in a report on Wednesday, November 29th. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Wednesday, October 4th. Finally, ValuEngine downgraded Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.

TRADEMARK VIOLATION WARNING: “Amyris Inc (AMRS) Insider Sells $50,431.68 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/18/amyris-inc-amrs-insider-sells-50431-68-in-stock.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply